CLINICAL TRIALS PROFILE FOR MIDOL LIQUID GELS

505(b)(2) Clinical Trials for MIDOL LIQUID GELS

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00262145 ↗	Ability of a Tea Leaf Extracts Preparation to Slow Down Carbohydrate and Fat Absorption	Completed	NatureGen	Phase 1	2005-10-01	Objective - A variety of herbal, over-the-counter preparations of tea leaves are said to reduce the rate of absorption of fat ( allegedly via inhibition of pancreatic lipase) and carbohydrate (via inhibition of carbohydrate digestion and blocking of glucose transport by the intestinal mucosa). There has been some study of the ability of these products to reduce the blood glucose increase observed after a carbohydrate meal and to reduce blood cholesterol levels in chronic studies. The purpose of the present study is to objectively determine if one cup of "tea" made from a combination of three types of tea leaves (mulberry, black and green tea) can cause malabsorption of carbohydrate and fat taken in conjunction with the tea. Research Design - The study will consist of a double blind, placebo controlled crossover study in 20 healthy subjects. On one of two days (one week apart) the subjects will ingest a standard meal consisting of 30 g of sucrose (in the tea) and 30 g of starch in the form of white rice plus 10 g of fat as butter. To measure triglyceride absorption, each meal will also contain 250 mg of 13-C labeled triolein. Triolein is a commonly ingested fat consisting of glycerol bound to three oleic acids. 13-C is a stable (non-radioactive) isotope of carbon. On one of the test days the subjects (randomly) will concurrently consume the active preparation, a tea containing extracts of the three types of tea leave described above plus the meal, and on the other test day they will consume the meal with a liquid placebo preparation (warm water, sugar and food coloring). Subjects will provide a breath sample before and at hourly intervals for 8 hours after ingestion of the meal. Carbohydrate malabsorption will be determined by the hydrogen concentration in the breath samples and fat malabsorption by the concentration of 13-CO2 in the breath samples. Clinical Significance - An increase in breath hydrogen indicates carbohydrate malabsoption and a low 13-CO2 indicates lipid malabsorption. Objective evidence that the tea leaf extract actually induces carbohydrate and/or fat malabsorption could provide the basis for further studies.
New Dosage	NCT00858936 ↗	Reduction of Ischemia-Reperfusion Mediated Cardiac Injury in Subjects Undergoing Coronary Artery Bypass Graft Surgery	Terminated	Mallinckrodt	Phase 2	2009-05-01	This clinical trial will investigate the safety and effectiveness of IK-1001 (the liquid form of sodium sulfide) when used in Coronary Artery Bypass Graft (CABG) patients to potentially reduce the damage done to the heart during surgery. This study has 2 parts. Part 1 will first test 36 subjects at different doses (amount) of the study drug. There will be 6 different groups of 6 subjects each that will receive the study drug or a placebo. A placebo is a substance that will be prepared to look like the study drug but will contain no active ingredients. In Part 1, five subjects from each group will receive study drug (IK-1001) and one will receive a placebo. This first part of this study is also a dose (amount) escalation. This means that each group will be receiving a different dose of the study drug. The first group will receive the lowest dose, the second group will receive a slightly higher dose, and the third group a slightly higher dose until all six groups has been tested. You can not choose which group you will be in but prior to starting each new dose level, the data (information) from the previous dose level will have been reviewed by a group of qualified individuals to determine if it is safe to proceed to the next highest dose level. Part 2 will expand the study and will treat at least 158 (and up to 632) more subjects at a dose level that has been deemed safe from information collected from Part 1. Subjects in Part 2 of the study will have a 1 in 2 (50%) chance of receiving the study drug or placebo. Whether the subject gets study drug or the placebo will be randomly assigned (like the toss of a coin). The study drug or placebo will be given as an intravenous infusion (into the vein) for six hours while the subject is having their CABG surgery. The subjects will be followed up for 6 months after their CABG surgery.
OTC	NCT00894634 ↗	Study Evaluating Brompheniramine Maleate Liquid in Children and Adolescents	Completed	Wyeth is now a wholly owned subsidiary of Pfizer	Phase 1	2009-03-21	The objective of this study is to characterize the pharmacokinetic (PK) profile of brompheniramine maleate (BROM) in children and adolescents, ages 2 to less than 18 years following dosing in accordance with current weight-age dosing guidelines. Once characterized, the PK data will be pooled with adult PK data from other studies and analyzed under a separate analysis plan to confirm or refine the existing OTC doses in children aged 2 to
New Formulation	NCT01267201 ↗	A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form	Completed	Pfizer	Phase 1	2010-11-01	A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers.

All Clinical Trials for MIDOL LIQUID GELS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000140 ↗	The Silicone Study	Completed	National Eye Institute (NEI)	Phase 3	1985-09-01	To compare, through a randomized, multicenter surgical trial, the postoperative tamponade effectiveness of intraocular silicone oil with that of an intraocular long-acting gas (initially sulfur hexafluoride [SF 6 ], later perfluoropropane [C 3 F 8 ]) for the management of retinal detachment complicated by proliferative vitreoretinopathy (PVR), using vitrectomy and associated techniques. To evaluate the ocular complications that result from the use of silicone oil and gas.
NCT00000302 ↗	Study Comparing Liquid and Tablet Buprenorphine Formulations - 5	Completed	National Institute on Drug Abuse (NIDA)	Phase 3	1969-12-31	The purpose of this study is to compare liquid and tablet buprenorphine formulations.
NCT00000320 ↗	Buprenorphine Formulation Comparison: Sublingual Tablet vs. Solution - 1	Completed	National Institute on Drug Abuse (NIDA)	Phase 1/Phase 2	1997-10-01	The purpose of this study is to compare subject response to liquid vs. tablet formulations, to assess bioequivalency of liquid vs. tablet, to compare subject preference, and to evaluate if dose response curve for tablet is equal to liquid form."
NCT00000341 ↗	Evaluation of Liquid vs. Tablet Buprenorphine - 6	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1996-08-01	The purpose of this study is to evaluate the steady-state pharmacokinetics and bioavailability of buprenorphine sublingual tablets vs. sublingual solution.

Clinical Trial Conditions for MIDOL LIQUID GELS

Condition Name

Condition Name for MIDOL LIQUID GELS
Intervention	Trials
Healthy	84
Breast Cancer	29
Healthy Volunteers	29
Obesity	26

Condition MeSH

Condition MeSH for MIDOL LIQUID GELS
Intervention	Trials
Diabetes Mellitus	53
Infections	46
Infection	40
Diabetes Mellitus, Type 2	40

Clinical Trial Locations for MIDOL LIQUID GELS

Trials by Country

Trials by Country for MIDOL LIQUID GELS
Location	Trials
Germany	96
Spain	86
France	81
Brazil	60
Australia	57

Trials by US State

Trials by US State for MIDOL LIQUID GELS
Location	Trials
California	176
Texas	149
New York	117
Ohio	105
Florida	105

Clinical Trial Progress for MIDOL LIQUID GELS

Clinical Trial Phase

Clinical Trial Phase for MIDOL LIQUID GELS
Clinical Trial Phase	Trials
PHASE4	26
PHASE3	15
PHASE2	34

Clinical Trial Status

Clinical Trial Status for MIDOL LIQUID GELS
Clinical Trial Phase	Trials
Completed	881
Recruiting	267
Not yet recruiting	141

Clinical Trial Sponsors for MIDOL LIQUID GELS

Sponsor Name

Sponsor Name for MIDOL LIQUID GELS
Sponsor	Trials
National Cancer Institute (NCI)	89
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	28
Bayer	28

Sponsor Type

Sponsor Type for MIDOL LIQUID GELS
Sponsor	Trials
Other	1857
Industry	754
NIH	228

Clinical Trials Update, Market Analysis, and Projection for Midol Liquid Gels

Last updated: October 30, 2025

Introduction

Midol Liquid Gels, a well-established over-the-counter medication, predominantly target relief from menstrual discomfort, including cramps, headaches, backache, and bloating. As a staple in women’s health, Midol’s formulation evolves with advances in clinical research and market dynamics. This report synthesizes recent clinical trial data, analyzes market trends, and provides future projections for Midol Liquid Gels, equipping pharmaceutical and business stakeholders with strategic insights.

---

Clinical Trials Update

Recent Clinical Research and Efficacy Studies

Over the past year, clinical investigations have primarily focused on optimizing formulations, assessing safety profiles, and expanding indications for Midol Liquid Gels. While existing formulations containing acetaminophen, caffeine, and pyrilamine have a longstanding safety profile, new trials aim to assess adjunct compounds or alternative dosing strategies.

Notably, a 2022 randomized controlled trial (RCT) published in Menstrual Health Journal evaluated a modified formulation combining higher doses of caffeine with non-steroidal anti-inflammatory agents (NSAIDs) to enhance pain relief. Results indicated improved efficacy in reducing menstrual pain severity compared to traditional formulations, with no significant increase in adverse events. This trial suggests potential for reformulation to bolster consumer satisfaction.

Safety and Tolerability Assessments

Safety evaluations conducted through phase IV post-marketing surveillance, coupled with clinical trial data, corroborate the safety profile of Midol Liquid Gels when used as directed. Mild side effects, such as gastrointestinal discomfort and restlessness, remain consistent with previous findings, reaffirming continued market viability.

Regulatory Advances

The FDA’s recent updates favor formulations with proven safety and efficacy. In 2023, the agency granted a new OTC monograph expansion for combination analgesic products, facilitating the approval pathway for reformulated Midol variants targeting broader demographics, including adolescents and peri-menopausal women.

---

Market Analysis

Current Market Landscape

The global analgesics market, specifically women’s health analgesics, is valued at approximately USD 4.2 billion in 2023, with a CAGR of 5.2% projected until 2030. Midol, as a prominent brand within this segment, benefits from strong brand recognition and extensive distribution channels in North America, Europe, and parts of Asia.

Segment-wise, OTC products for menstrual pain, including Midol and alternatives like Pamprin and Menstrual Pain Relief, collectively hold over 40% of the women's OTC analgesics market. Consumer preference shifts towards fast-acting formulations favor liquid gels due to their rapid absorption over tablets.

Competitive Dynamics

Key competitors include:

• Triaminic Menstrual Pain Relief (marketed by Johnson & Johnson)
• Pamprin Multi-Symptom (Reckitt Benckiser)
• Emerging natural and herbal alternatives, capitalizing on holistic health trends.

Innovations in formulations, such as caffeine-free versions or natural extracts, pose competitive threats. However, Midol’s prominent market share benefits from longstanding consumer trust and wide availability.

Consumer Trends and Preferences

Recent surveys indicate increased demand for relief options that combine multi-symptom management with minimal side effects. The rise of digital health platforms and direct-to-consumer marketing has amplified awareness, particularly among younger demographics and peri-menopausal women seeking tailored solutions.

The preference for liquid gels aligns with the rising consumer demand for convenience, quick efficacy, and portable formats. Additionally, there is a surge in interest toward non-drowsy formulations and natural ingredient inclusion, influencing R&D directions.

Regulatory and Market Entry Barriers

High regulatory standards ensure safety and efficacy but pose entry hurdles for new formulations. Patent expirations for certain active ingredients are driving innovation and reformulation efforts; however, strict labeling regulations and OTC monograph compliance require substantial investment.

---

Market Projections and Future Outlook

Growth Trajectory

Based on current trends, the global OTC menstrual pain relief market is expected to grow at a CAGR of approximately 6% through 2030. The rising prevalence of menstrual disorders, coupled with increasing health awareness, underscores sustained demand.

Midol Liquid Gels are positioned favorably within this landscape, especially as reformulations and new segment introductions emerge. By leveraging clinical trial data to underpin efficacy claims, Midol can solidify its market dominance.

Innovation and Expansion Opportunities

• Formulation Diversification: Development of caffeine-free or natural ingredient-based options targeting health-conscious consumers.
• Indication Expansion: Exploring off-label uses for related pain conditions (e.g., general cramps, migraine prophylaxis).
• Digital Engagement: Utilizing telemedicine and e-commerce platforms to reach younger consumers and peri-menopausal demographics.
• Geographical Expansion: Targeting emerging markets in Asia and Latin America, where menstrual product markets are expanding rapidly.

Potential Challenges

• Competition from herbal and natural products.
• Regulatory barriers in emerging markets.
• Consumer skepticism regarding drug safety amidst rising natural remedy adoption.
• Patent expiration risks, opening pathways for generic formulations.

---

Strategic Recommendations

• Invest in Clinical Trials: Continue research on formulation enhancements, focusing on safety, efficacy, and indications to support marketing claims.

• Product Diversification: Launch new variants aligned with current consumer preferences, including caffeine-free and natural ingredients.

• Market Penetration: Strengthen retail distribution and digital marketing targeting key segments—adolescents through young women, and peri-menopausal women.

• Regulatory Compliance: Engage proactively with regulatory agencies to facilitate approvals of new formulations and indications.

• Global Expansion: Tailor regional strategies addressing local regulatory requirements, cultural preferences, and market needs.

---

Key Takeaways

• Efficacy & Safety: Recent clinical trials affirm Midol Liquid Gels' effectiveness in menstrual pain relief, with a consistent safety profile supporting its OTC status.

• Market Position: Midol maintains a leading position in the women’s OTC analgesics segment, especially with liquid gel formats favored for rapid action.

• Growth Drivers: Rising prevalence of menstrual discomfort, consumer preference for convenience, and product innovation propel future growth.

• Competitive Edge: Leveraging clinical research for reformulation and expanding indications will bolster Midol's competitive advantage amidst natural and herbal alternatives.

• Strategic Focus: Emphasizing diversification, geographical expansion, and digital engagement provides pathways to capitalize on emerging market opportunities.

---

FAQs

1. Are there any recent clinical trials indicating new indications for Midol Liquid Gels?
Currently, clinical research continues to focus on optimizing formulations rather than expanding indications. While some trials investigate adjunct ingredients for enhanced relief, no new indications have been officially approved as of 2023.

2. How does Midol Liquid Gels compare to other menstrual pain relief products in efficacy?
Clinical data suggest Midol Liquid Gels provide rapid and effective relief comparable or superior to traditional oral tablets, owing to faster absorption through liquid gel formulation. Consumer reviews reinforce these findings.

3. What are the regulatory challenges for reformulating or expanding Midol’s indications?
Reformulation and indication expansion require rigorous clinical testing to meet FDA or EMA standards. The OTC monograph process entails demonstrating safety and efficacy, which can be resource-intensive.

4. Will market trends favor natural or herbal alternatives over Midol Liquid Gels?
While natural remedies are gaining popularity, Midol’s established efficacy and safety profile sustain its market; however, integrating natural ingredients into formulations could be a strategic response to evolving consumer preferences.

5. What are the prospects for Midol Liquid Gels in emerging markets?
Significant growth opportunities exist due to increasing awareness and product accessibility. Customized marketing strategies and regulatory compliance are critical to successful entry and expansion.

---

References

1. Menstrual Health Journal. (2022). Efficacy of Modified Formulations in Menstrual Pain Relief.
2. MarketWatch. (2023). Global Over-the-Counter Analgesics Market Report.
3. FDA. (2023). Over-the-Counter Monograph Modernization.
4. Euromonitor International. (2023). Women’s Health OTC Products Market Analysis.
5. Statista. (2023). Consumer Preferences for Menstrual Pain Relief Formats.

---

This comprehensive analysis enables decision-makers to align clinical innovation, market strategies, and regulatory pathways, ensuring Midol Liquid Gels sustain and enhance its market leadership in women’s health analgesics.